Radvac Biomedical Countermeasures White Papers

Modernized Variolation

October 1, 2026

Radvac has begun work to study, modernize, and improve the immunization strategy of variolation. Historical versions of variolation predate modern vaccination but conferred unique benefits including rapid deployability, direct immunologic relevance to a pathogen at hand, and applicability to a broad spectrum of pathogens (approaching pathogen agnostic usefulness).

Click here to access the first modernized variolation white paper.

Radvac adopts Prime and Spike and discontinues use of chitosan-peptide vaccine formulations

June 24, 2024

Due to cost, availability, and published efficacy data of another vaccine design, Radvac has discontinued its use of its original chitosan and peptide vaccine platform, and has replaced it with the “Prime and Spike” approach published by Mao and colleagues. See here for more details.

Open-Source Peptide Vaccine Platform White Papers:

Click here to access the latest version of the Radvac White Paper on the SARS-CoV-2 peptide vaccine rationale, design, materials, protocols, and testing.

Aug 13, 2022: White paper version 5-2-2. This update provides the Generation 13 vaccine design, including immunogens from multiple Omicron variants.

Clinical Step-Up Challenge Trial White Papers

Click here to access the latest version of the Radvac White Paper on a Step-Up Challenge Trial Design and Rationale.

April 10, 2022: Version 1-1-0. To contribute to future drafts, you can access our next working draft through the Radvac Project Discord server.

Archive

Older versions of the Radvac white paper on the SARS-CoV-2 peptide vaccine platform are available below: